Invention Grant
US08258288B2 RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA) 有权
使用短干扰核酸(siNA)的RNA干扰介导的呼吸道合胞病毒(RSV)表达的抑制

  • Patent Title: RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
  • Patent Title (中): 使用短干扰核酸(siNA)的RNA干扰介导的呼吸道合胞病毒(RSV)表达的抑制
  • Application No.: US12247971
    Application Date: 2008-10-08
  • Publication No.: US08258288B2
    Publication Date: 2012-09-04
  • Inventor: James McSwiggenLeonid Beigelman
  • Applicant: James McSwiggenLeonid Beigelman
  • Applicant Address: US CO Boulder
  • Assignee: Sirna Therapeutics, Inc.
  • Current Assignee: Sirna Therapeutics, Inc.
  • Current Assignee Address: US CO Boulder
  • Agent Laura M. Ginkel; David A. Muthard
  • Main IPC: C07H21/04
  • IPC: C07H21/04
RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
Abstract:
This invention relates to compounds, compositions, and methods useful for modulating sespiratory syncytial virus (RSV) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of RSV gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of RSV genes, including cocktails of such small nucleic acid molecules and lipid nanoparticle formulations of such small nucleic acid molecules cocktails thereof. The application also relates to methods of treating diseases and conditions associated with RSV gene expression, such as RSV infection, respiratory failure, bronchiolitis and pneumonia, as well as providing dosing regimens and treatment protocols.
Information query
Patent Agency Ranking
0/0